About Daiichi Sankyo Group Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose "to contribute to the enrichment of quality of life around the world." In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs
Inconsistent administration Skipping doses, irregular timing, and forgotten applications all reduce effectiveness
As they promote weight loss, Semaglutide GLP-1 injections reduce the risk of complications associated with obesity, such as cardiovascular disease, high blood pressure, and high cholesterol
A 350-calorie meal with 35 g protein, fluids, and some fiber is very different from a 350-calorie meal of crackers that leaves the daily protein gap untouched
doi:10.1111/jdv.20197 15
Independent editorial review